VEGF plasma level variations in duloxetine-treated patients with major depression

Michele Fornaro, Giulio Rocchi, Andrea Escelsior, Paola Contini, Massimo Ghio, Salvatore Colicchio, Domenico De Berardis, Mario Amore, Pantaleo Fornaro, Matteo Martino

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background The vascular endothelial growth factor (VEGF) signaling, which modulates angiogenesis and neurogenesis within the neurovascular unit, might play an important role in the neuro-endocrine-immune (NEI) stress-adaptation system. Recent evidence suggests that VEGF is involved in the pathophysiology of a number of diseases including major depressive disorder (MDD) and is affected by some treatments, including antidepressants. The objective of the study was to investigate the VEGF level variations in MDD patients during antidepressant treatment with duloxetine, a relatively new SNRI. Methods A total of 30 MDD patients and 32 healthy controls were assessed using the Hamilton Depression Scale (HAM-D) and monitored for VEGF plasma levels at baseline, week 6 and week 12 of duloxetine treatment (60 mg/day) and at baseline, respectively. Results According to early clinical response to duloxetine (defined at week 6 by reduction>50% of baseline HAM-D score), the MDD patients were divided into early responders (ER) and early non-responders (ENR). During duloxetine treatment, we found an opposite trend in the VEGF levels between ER and ENR: in ER the VEGF levels significantly increased in association with clinical response at W6, while in ENR the VEGF levels significantly decreased in association with an overall clinical response at W12. Limitations Small sample size. Conclusions The opposite trends in VEGF levels, increasing in ER and decreasing in ENR, might reflect differential Norepinephrine/Serotonin effects of duloxetine on differential neurobiological backgrounds of depressive syndromes. Overall, the modulation of VEGF signaling within the neurovascular unit during antidepressant treatment could hypothetically favor the remodeling of neural circuitry, contributing to adaptive adjustment of the NEI stress-adaptation system.

Original languageEnglish
Pages (from-to)590-595
Number of pages6
JournalJournal of Affective Disorders
Volume151
Issue number2
DOIs
Publication statusPublished - Nov 1 2013
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Depression
Major Depressive Disorder
Antidepressive Agents
Serotonin Agents
Therapeutics
Social Adjustment
Duloxetine Hydrochloride
Neurogenesis
Depressive Disorder
Sample Size
Norepinephrine

Keywords

  • Depression
  • Duloxetine
  • Neurovascular unit
  • VEGF

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

VEGF plasma level variations in duloxetine-treated patients with major depression. / Fornaro, Michele; Rocchi, Giulio; Escelsior, Andrea; Contini, Paola; Ghio, Massimo; Colicchio, Salvatore; De Berardis, Domenico; Amore, Mario; Fornaro, Pantaleo; Martino, Matteo.

In: Journal of Affective Disorders, Vol. 151, No. 2, 01.11.2013, p. 590-595.

Research output: Contribution to journalArticle

Fornaro, M, Rocchi, G, Escelsior, A, Contini, P, Ghio, M, Colicchio, S, De Berardis, D, Amore, M, Fornaro, P & Martino, M 2013, 'VEGF plasma level variations in duloxetine-treated patients with major depression', Journal of Affective Disorders, vol. 151, no. 2, pp. 590-595. https://doi.org/10.1016/j.jad.2013.06.055
Fornaro M, Rocchi G, Escelsior A, Contini P, Ghio M, Colicchio S et al. VEGF plasma level variations in duloxetine-treated patients with major depression. Journal of Affective Disorders. 2013 Nov 1;151(2):590-595. https://doi.org/10.1016/j.jad.2013.06.055
Fornaro, Michele ; Rocchi, Giulio ; Escelsior, Andrea ; Contini, Paola ; Ghio, Massimo ; Colicchio, Salvatore ; De Berardis, Domenico ; Amore, Mario ; Fornaro, Pantaleo ; Martino, Matteo. / VEGF plasma level variations in duloxetine-treated patients with major depression. In: Journal of Affective Disorders. 2013 ; Vol. 151, No. 2. pp. 590-595.
@article{65fe51661f1f44ae8561c77bc3c1b7b7,
title = "VEGF plasma level variations in duloxetine-treated patients with major depression",
abstract = "Background The vascular endothelial growth factor (VEGF) signaling, which modulates angiogenesis and neurogenesis within the neurovascular unit, might play an important role in the neuro-endocrine-immune (NEI) stress-adaptation system. Recent evidence suggests that VEGF is involved in the pathophysiology of a number of diseases including major depressive disorder (MDD) and is affected by some treatments, including antidepressants. The objective of the study was to investigate the VEGF level variations in MDD patients during antidepressant treatment with duloxetine, a relatively new SNRI. Methods A total of 30 MDD patients and 32 healthy controls were assessed using the Hamilton Depression Scale (HAM-D) and monitored for VEGF plasma levels at baseline, week 6 and week 12 of duloxetine treatment (60 mg/day) and at baseline, respectively. Results According to early clinical response to duloxetine (defined at week 6 by reduction>50{\%} of baseline HAM-D score), the MDD patients were divided into early responders (ER) and early non-responders (ENR). During duloxetine treatment, we found an opposite trend in the VEGF levels between ER and ENR: in ER the VEGF levels significantly increased in association with clinical response at W6, while in ENR the VEGF levels significantly decreased in association with an overall clinical response at W12. Limitations Small sample size. Conclusions The opposite trends in VEGF levels, increasing in ER and decreasing in ENR, might reflect differential Norepinephrine/Serotonin effects of duloxetine on differential neurobiological backgrounds of depressive syndromes. Overall, the modulation of VEGF signaling within the neurovascular unit during antidepressant treatment could hypothetically favor the remodeling of neural circuitry, contributing to adaptive adjustment of the NEI stress-adaptation system.",
keywords = "Depression, Duloxetine, Neurovascular unit, VEGF",
author = "Michele Fornaro and Giulio Rocchi and Andrea Escelsior and Paola Contini and Massimo Ghio and Salvatore Colicchio and {De Berardis}, Domenico and Mario Amore and Pantaleo Fornaro and Matteo Martino",
year = "2013",
month = "11",
day = "1",
doi = "10.1016/j.jad.2013.06.055",
language = "English",
volume = "151",
pages = "590--595",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - VEGF plasma level variations in duloxetine-treated patients with major depression

AU - Fornaro, Michele

AU - Rocchi, Giulio

AU - Escelsior, Andrea

AU - Contini, Paola

AU - Ghio, Massimo

AU - Colicchio, Salvatore

AU - De Berardis, Domenico

AU - Amore, Mario

AU - Fornaro, Pantaleo

AU - Martino, Matteo

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Background The vascular endothelial growth factor (VEGF) signaling, which modulates angiogenesis and neurogenesis within the neurovascular unit, might play an important role in the neuro-endocrine-immune (NEI) stress-adaptation system. Recent evidence suggests that VEGF is involved in the pathophysiology of a number of diseases including major depressive disorder (MDD) and is affected by some treatments, including antidepressants. The objective of the study was to investigate the VEGF level variations in MDD patients during antidepressant treatment with duloxetine, a relatively new SNRI. Methods A total of 30 MDD patients and 32 healthy controls were assessed using the Hamilton Depression Scale (HAM-D) and monitored for VEGF plasma levels at baseline, week 6 and week 12 of duloxetine treatment (60 mg/day) and at baseline, respectively. Results According to early clinical response to duloxetine (defined at week 6 by reduction>50% of baseline HAM-D score), the MDD patients were divided into early responders (ER) and early non-responders (ENR). During duloxetine treatment, we found an opposite trend in the VEGF levels between ER and ENR: in ER the VEGF levels significantly increased in association with clinical response at W6, while in ENR the VEGF levels significantly decreased in association with an overall clinical response at W12. Limitations Small sample size. Conclusions The opposite trends in VEGF levels, increasing in ER and decreasing in ENR, might reflect differential Norepinephrine/Serotonin effects of duloxetine on differential neurobiological backgrounds of depressive syndromes. Overall, the modulation of VEGF signaling within the neurovascular unit during antidepressant treatment could hypothetically favor the remodeling of neural circuitry, contributing to adaptive adjustment of the NEI stress-adaptation system.

AB - Background The vascular endothelial growth factor (VEGF) signaling, which modulates angiogenesis and neurogenesis within the neurovascular unit, might play an important role in the neuro-endocrine-immune (NEI) stress-adaptation system. Recent evidence suggests that VEGF is involved in the pathophysiology of a number of diseases including major depressive disorder (MDD) and is affected by some treatments, including antidepressants. The objective of the study was to investigate the VEGF level variations in MDD patients during antidepressant treatment with duloxetine, a relatively new SNRI. Methods A total of 30 MDD patients and 32 healthy controls were assessed using the Hamilton Depression Scale (HAM-D) and monitored for VEGF plasma levels at baseline, week 6 and week 12 of duloxetine treatment (60 mg/day) and at baseline, respectively. Results According to early clinical response to duloxetine (defined at week 6 by reduction>50% of baseline HAM-D score), the MDD patients were divided into early responders (ER) and early non-responders (ENR). During duloxetine treatment, we found an opposite trend in the VEGF levels between ER and ENR: in ER the VEGF levels significantly increased in association with clinical response at W6, while in ENR the VEGF levels significantly decreased in association with an overall clinical response at W12. Limitations Small sample size. Conclusions The opposite trends in VEGF levels, increasing in ER and decreasing in ENR, might reflect differential Norepinephrine/Serotonin effects of duloxetine on differential neurobiological backgrounds of depressive syndromes. Overall, the modulation of VEGF signaling within the neurovascular unit during antidepressant treatment could hypothetically favor the remodeling of neural circuitry, contributing to adaptive adjustment of the NEI stress-adaptation system.

KW - Depression

KW - Duloxetine

KW - Neurovascular unit

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84885471898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885471898&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2013.06.055

DO - 10.1016/j.jad.2013.06.055

M3 - Article

C2 - 23871390

AN - SCOPUS:84885471898

VL - 151

SP - 590

EP - 595

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 2

ER -